Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediate‐Early 2 Protein, a Promising Target for Anti‐HCMV Treatment
- 11 June 2013
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 8 (8) , 1403-1414
Abstract
Although human cytomegalovirus (HCMV) infection is mostly asymptomatic for immunocompetent individuals, it remains a serious threat for those who are immunocompromised, in whom it is associated with various clinical manifestations. The therapeutic utility of the few available anti‐HCMV drugs is limited by several drawbacks, including cross‐resistance due to their common mechanism of action, i.e., inhibition of viral DNA polymerase. Therefore, compounds that target other essential viral events could overcome this problem. One example of this is the 6‐aminoquinolone WC5, which acts by directly blocking the transactivation of essential viral Early genes by the Immediate‐Early 2 (IE2) protein. In this study, the quinolone scaffold of the lead compound WC5 was investigated in depth, defining more suitable substituents for each of the scaffold positions explored and identifying novel, potent and nontoxic compounds. Some compounds showed potent anti‐HCMV activity by interfering with IE2‐dependent viral E gene expression. Among them, naphthyridone 1 was also endowed with potent anti‐HIV activity in latently infected cells. Their antiviral profile along with their innovative mechanism of action make these anti‐HCMV quinolones a very promising class of compounds to be exploited for more effective antiviral therapeutic treatment.Keywords
This publication has 37 references indexed in Scilit:
- Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectivesPharmacology & Therapeutics, 2011
- The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 ProteinAntimicrobial Agents and Chemotherapy, 2010
- In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246Antimicrobial Agents and Chemotherapy, 2010
- A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus ActivityAntimicrobial Agents and Chemotherapy, 2009
- New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activityJournal of Applied Microbiology, 2008
- Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years laterNature Protocols, 2008
- Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone DerivativesAntimicrobial Agents and Chemotherapy, 2007
- Selective Anti-Cytomegalovirus Compounds Discovered by Screening for Inhibitors of Subunit Interactions of the Viral PolymeraseChemistry & Biology, 2006
- The Putative Zinc Finger of the Human Cytomegalovirus IE2 86-Kilodalton Protein Is Dispensable for DNA Binding and Autorepression, Thereby Demarcating a Concise Core Domain in the C Terminus of the ProteinJournal of Virology, 2004
- Cycloaracylierung von Enaminen, II. Synthese von 1‐Amino‐4‐chinolon‐3‐carbonsäurenEuropean Journal of Organic Chemistry, 1987